Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
US Department of Justice
AstraZeneca
Cerilliant
QuintilesIMS
Boehringer Ingelheim
Citi
Harvard Business School
Federal Trade Commission
Johnson and Johnson

Generated: August 19, 2017

DrugPatentWatch Database Preview

Depomed Inc Company Profile

« Back to Dashboard

What is the competitive landscape for DEPOMED INC, and when can generic versions of DEPOMED INC drugs launch?

DEPOMED INC has eight approved drugs.

There are thirty-five US patents protecting DEPOMED INC drugs.

There are four hundred and seventy-four patent family members on DEPOMED INC drugs in forty-nine countries.

Summary for Applicant: Depomed Inc

Patents:35
Tradenames:7
Ingredients:5
NDAs:8
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-003Aug 25, 2011RXYesNo► Subscribe► Subscribe ► Subscribe
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-005Aug 25, 2011RXYesYes► Subscribe► SubscribeYY ► Subscribe
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-004Aug 25, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-003Aug 25, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Depomed Inc
CAMBIA
diclofenac potassium
FOR SOLUTION;ORAL022165-001Jun 17, 2009ABRXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Depomed Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Depomed Inc
CAMBIA
diclofenac potassium
FOR SOLUTION;ORAL022165-001Jun 17, 2009► Subscribe► Subscribe
Depomed Inc
GRALISE
gabapentin
TABLET;ORAL022544-002Jan 28, 2011► Subscribe► Subscribe
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-003Aug 25, 2011► Subscribe► Subscribe
Depomed Inc
CAMBIA
diclofenac potassium
FOR SOLUTION;ORAL022165-001Jun 17, 2009► Subscribe► Subscribe
Depomed Inc
NUCYNTA
tapentadol hydrochloride
TABLET;ORAL022304-001Nov 20, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for DEPOMED INC drugs

Drugname Dosage Strength Tradename Submissiondate
tapentadol
Oral Solution20 mg/mL
NUCYNTA
12/30/2013
tapentadol
Oral Solution20 mg/mL
NUCYNTA
12/20/2013
tapentadol hydrochloride
Tabletsx50 mg, 75 mg, and 100 mg
NUCYNTA
11/20/2012
tapentadol hydrochloride
Extended-release Tablets50 mg, 100 mg, 150 mg, 200 mg, and 250 mg
NUCYNTA ER
11/20/2012
diclofenac potassium
Capsules25 mg
ZIPSOR
11/14/2012
gabapentin
Tablets300 mg and 600 mg
GRALISE
10/31/2011
diclofenac
Potassium Oral Solution (Sachet)50 mg
CAMBIA
1/24/2011

Non-Orange Book Patents for Depomed Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,087,765Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases► Subscribe
8,114,384Process for the production of an abuse-proofed solid dosage form► Subscribe
8,323,889Process for the production of an abuse-proofed solid dosage form► Subscribe
8,802,157Methods of treatment using a gastric retained gabapentin dosage form► Subscribe
8,475,813Methods of treatment using a gastric retained gabapentin dosage► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Depomed Inc Drugs

Country Document Number Estimated Expiration
Japan4083818► Subscribe
EcuadorSP077989► Subscribe
Slovenia1845956► Subscribe
Hong Kong1100639► Subscribe
TaiwanI312285► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Depomed Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014000024Germany► SubscribePRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
90004-0.LSweden► SubscribePRODUCT NAME: TAPENTADOL; NAT. REG. NO/DATE: 42622-42628 20100910; FIRST REG.: DE 7543-7548,7661-76270" EESGODKLANDKOD="DE" EESGODKDATUM="2010-08-19" SEGODKNR="42622-42628 20100819
2011007,C0693475Lithuania► SubscribePRODUCT NAME: TAPENTADOLUM; NAT. REGISTRATION NO/DATE: LT/1/10/2341/001 - LT/1/10/2341/66, 2011 02 19; LT/1/10/2342/001 - LT/1/10/2342/110 20110219; FIRST REGISTRATION: 75043.00.00 - 75048.00.00, 2010 08 19; 76261.00.00 - 76270.00.00 20100819
0653Netherlands► SubscribePRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Colorcon
Covington
Citi
Medtronic
Moodys
US Army
Queensland Health
Julphar
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot